If AMBS completes enrollment for LP-002 protocol on all the remaining sites, then run the test and analyze it in time to present on or before the next shareholders meeting would be tremendous. That would prove what GC stated in his blog about his teams ability at "establishing a well-oiled clinical organization capable of translating protocols to practice, and ultimately to data at a very rapid pace".

I believe a lot of us on this board got in $AMBS way before LYMPRO was brought in to the picture. AMBS very methodically has increased the value of the company and has reduced the risk for shareholders who see this as a long term investment.